Xenon Pharmaceuticals Q3 2024 Earnings Report $41.32 +0.04 (+0.10%) (As of 10:57 AM ET) Earnings HistoryForecast Xenon Pharmaceuticals EPS ResultsActual EPS-$0.81Consensus EPS -$0.82Beat/MissBeat by +$0.01One Year Ago EPS-$0.73Xenon Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AXenon Pharmaceuticals Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptXENE Earnings History Forbes rich list released… #1 to be assassinated? (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Xenon Pharmaceuticals Earnings HeadlinesPromising Efficacy and Tolerability: Douglas Tsao’s Buy Rating on Xenon Pharmaceuticals’ AzetukalnerDecember 12, 2024 | markets.businessinsider.comPromising Phase IIb Data and Pipeline Advancements Drive Buy Rating for XenonDecember 10, 2024 | markets.businessinsider.comForbes rich list released… #1 to be assassinated?Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.December 18, 2024 | Porter & Company (Ad)Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024December 6, 2024 | globenewswire.comXenon Pharmaceuticals Inc. Announces Multiple Poster Presentations at AES 2024 Featuring New Data on Azetukalner and Nav1.1 ProgramNovember 25, 2024 | quiverquant.comXenon to Showcase New Long-Term Azetukalner Data at AES 2024November 25, 2024 | globenewswire.comSee More Xenon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xenon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenon Pharmaceuticals and other key companies, straight to your email. Email Address About Xenon PharmaceuticalsXenon Pharmaceuticals (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.View Xenon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
